Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

Women with certain types of ovarian and breast cancers are benefiting from a relatively new class of drugs known as PARP inhibitors. Soon, men with advanced prostate cancer might be helped, too.

Clovis Oncology (CLVS) disclosed new clinical trial results Friday showing a 44 percent tumor response rate following treatment with its PARP inhibitor, called Rubraca. The median duration of response has not yet been reached.

The 25 men enrolled in Clovis’ clinical trial all have advanced prostate cancer no longer responsive to at least two other therapies, including chemotherapy and the androgen-targeted drugs Zytiga and Xtandi. The prostate cancer cells in these men also contain mutations to the BRCA gene, which makes the tumors more vulnerable to PARP inhibitors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In